What Eugia Pharma Specialities Ltd does

Eugia Pharma Specialities Ltd is a Hyderabad, India-headquartered specialty generics pharmaceutical manufacturer founded in 2013 with approximately 1,627 employees. The company focuses on three high-barrier therapeutic categories — sterile injectable pharmaceuticals, oncology products, and hormonal products — supported by in-house Research & Development capabilities and world-class manufacturing facilities. The company is the specialty injectables and steriles arm of its promoter, Aurobindo Pharma, and distributes directly to healthcare providers, hospitals, and pharmacies.

The company operates a global commercial footprint spanning more than 25 countries across North America, South America, Europe, Africa, the Middle East, Central Asia, and Oceania, with dedicated country-level commercial sites in the United States, Canada, and Australia. Marketing is conducted primarily through corporate website content and media relations (press releases, news updates, blogs), and the company maintains specialized functions including investor relations, pharmacovigilance (adverse event reporting), and HR recruitment.

Commercially, Eugia is a private company with no public stock ticker or exchange listing. Pricing is quote-based and not publicly disclosed. No revenue figure, funding round, M&A activity, leadership profile, or AI/technology capability is disclosed in the available source data. Ownership details beyond the Aurobindo Pharma promoter relationship are not disclosed.

Name

Eugia Pharma Specialities Ltd

Legal name

Eugia Pharma Specialities Ltd

Website

https://eugiapharma.com

Company type

Private

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Eugia Pharma Specialities Ltd is a Hyderabad-based specialty generics pharmaceutical manufacturer founded in 2013, producing sterile injectables, oncology, and hormonal products for healthcare providers across 25+ countries. It operates as the specialty injectables arm of promoter Aurobindo Pharma.

Ownership category

akta.pro rank

Product category

Specialty Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

akta.pro secondary industry

Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD)

Keywords

• Specialty generic pharmaceuticals
• Sterile injectable manufacturing
• Oncology generic drugs
• Hormonal therapeutic products
• Pharmaceutical contract manufacturing

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Distribution channels1 record

Marketing channels2 records

Core offering

Eugia Pharma Specialities Ltd is a global specialty generics pharmaceutical manufacturer that develops, produces, and supplies sterile injectable products across oncology and hormonal therapeutic areas. The company supports its portfolio with in-house research and development capabilities and operates world-class manufacturing facilities to deliver compliant specialty generics to healthcare providers and pharmacies worldwide.

Product overview

Eugia Pharma Specialities Ltd is a global specialty generics company offering a unified portfolio of injectable pharmaceuticals and sterile products. The company's core offerings span key therapeutic areas including oncology, hormonal treatments, and steriles, supported by in-house Research & Development capabilities and world-class manufacturing facilities. The specialty generics portfolio represents the company's primary product line, with therapeutic focus areas and manufacturing capabilities integrated to deliver specialty pharmaceutical solutions globally.

Differentiator

Problem solved

Functional benefit

Products and services

• Specialty Generics Portfolio Core specialty generics portfolio of injectable pharmaceuticals and sterile products targeting oncology and hormonal therapeutic areas, offered to healthcare providers and pharmacies globally.
• Sterile Injectable Pharmaceuticals Sterile injectable pharmaceutical products manufactured for safety and efficacy in hospital and clinical healthcare settings.
• Oncology Specialty Generics Specialty generic pharmaceutical products targeting oncology treatments for cancer care.
• Hormonal Specialty Generics Specialty generic hormonal pharmaceutical products for various therapeutic applications.
• Pharmaceutical Research and Development Services In-house R&D capabilities supporting innovation and development of specialty generic pharmaceutical formulations.
• Pharmaceutical Manufacturing Facilities World-class manufacturing units producing pharmaceutical products for commercial supply to global markets.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• Aurobindo Pharma: Aurobindo Pharma is the promoter and parent of Eugia Pharma; it is one of India's largest generic pharmaceutical manufacturers with a broad portfolio across oral solids, sterile injectables, and specialty products, making it the most directly comparable reference for Eugia's specialty-generics/sterile injectable focus.
• Sandoz (Novartis): Sandoz is the global leader in off-patent medicines, with a growing specialty generics and injectable franchise across oncology, anti-infectives, and complex injectables, directly comparable to Eugia's specialty-generics injectable focus.
• Fresenius Kabi: Fresenius Kabi is a leading global specialist in sterile injectable pharmaceuticals, IV generics, and complex specialty products; it represents the global benchmark in Eugia's exact niche of sterile injectable specialty generics for hospitals.
• Sun Pharmaceutical Industries: Sun Pharma is India's largest specialty and generic pharmaceutical company with significant sterile injectable, hormonal, and oncology franchises across global markets, providing a direct like-for-like benchmark for Eugia's business model and global expansion strategy.
• Viatris (Mylan): Viatris (formed via Mylan-Upjohn combination) has a broad specialty/generic injectable franchise including oncology injectables and sterile hospital products globally, making it a relevant benchmark for Eugia's specialty injectable generics positioning.
• Pfizer (Hospira Injectables): Post-Hospira acquisition, Pfizer operates one of the world's largest sterile injectable portfolios for hospitals in the US and globally; it competes with Eugia in the same institutional injectable generics and specialty injectable space.

Direct peers

• Dr. Reddy's Laboratories: Dr. Reddy's is a major Indian-headquartered generic pharmaceutical manufacturer with a significant sterile injectables and specialty oncology presence, including US- and EU-focused generic injectable franchises that directly overlap with Eugia's specialty sterile injectables and oncology portfolio.
• Cipla Limited: Cipla is a major Indian generic pharmaceutical company with growing injectable and specialty pharmaceutical operations across the US, Europe, and emerging markets, directly comparable to Eugia's specialty injectable positioning and footprint.
• Lupin Limited: Lupin is an India-based global generic player with substantial complex generics, sterile injectables, and specialty franchises in US and EU regulated markets, making it a closely comparable operator to Eugia's specialty-generics and sterile-injectable business.
• Gland Pharma: Gland Pharma is an India-based specialty injectables manufacturer with a global footprint (acquired by China's Fosun), focused on sterile injectables and complex generics for regulated markets; it represents one of the closest pure-play comparables to Eugia.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/eugia-pharma-specialities-ltd

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eugia Pharma Specialities Ltd